|
|
ImmunoGen, Inc.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Re: possible 936 combo in future. NSCLC MerckWith 245 patients in a Phase 1/2 Trial, do you think the trial could be registration possibly expanded to do so. If not, I'd think it could transition into a Phase 3 so all patients in the Phase 2 portion would be part of the Phase 3 and fewer total patients would be needed. Here's a link to that trial: https://clinicaltrials.gov/ct2/show/NCT04622774 Gary |
||||||||||||
|
|
return to message board, top of board |
| Msg # | Subject | Author | Recs | Date Posted |
| 56018 | Re: possible 936 combo in future. NSCLC Merck | pierre piav | 1 | 5/29/2023 8:49:13 AM |
